Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Elegance: Drug-Eluting Registry-Real-World Treatment of Lesions in the Peripheral Vasculature

Clinical Trial Details

The purpose of this study is to collect data on the use of commercially approved Boston Scientific drug-eluting devices used to treat peripheral vascular disease (PAD) to understand how these devices are being used in a routine hospital setting. We hope to potentially improve patient outcomes in the future as well as to understand how patient outcomes compare across diverse patient populations. The study data will also be used to continue monitoring the safety of these devices.

All visits are per standard of care and there are no separate study visits required. 

Key Eligibility: 
  1. Open to men and women above the age of 18 who have been diagnosed with Peripheral Vascular Disease (PAD). 
  2. Participants can be enrolled if treated with commercially available BSC drug-eluting devices marketed for treatment of lesions located in the peripheral vasculature.

Study contact by location

Upper East Side - Manhattan

Contact(s)

Rosa Aurora Chu
roc2025@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

2206024976

ClinicalTrials.gov:

NCT04674969

Sponsor:

S2444

Status

Open to Enrollment

Age Group

Adult

Sponsor